Selected article for: "antiviral drug and fatality rate"
Author: Cheng, Kai-Wen; Cheng, Shu-Chun; Chen, Wei-Yi; Lin, Min-Han; Chuang, Shang-Ju; Cheng, I-Hsin; Sun, Chiao-Yin; Chou, Chi-Yuan
Title: Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
  • Cord-id: zj34cb6f
  • Document date: 2014_12_24
    • ID: zj34cb6f
    Snippet: Middle East respiratory syndrome coronavirus (MERS-CoV) is a new highly pathogenic human coronaviruses that emerged in Jeddah and Saudi Arabia and has quickly spread to other countries in Middle East, Europe and North Africa since 2012. Up to 17 December 2014, it has infected at least 938 people with a fatality rate of about 36% globally. This has resulted in an urgent need to identify antiviral drugs that are active against MERS-CoV. The papain-like protease (PL(pro)) of MERS-CoV represents an
    Document: Middle East respiratory syndrome coronavirus (MERS-CoV) is a new highly pathogenic human coronaviruses that emerged in Jeddah and Saudi Arabia and has quickly spread to other countries in Middle East, Europe and North Africa since 2012. Up to 17 December 2014, it has infected at least 938 people with a fatality rate of about 36% globally. This has resulted in an urgent need to identify antiviral drugs that are active against MERS-CoV. The papain-like protease (PL(pro)) of MERS-CoV represents an important antiviral target as it is not only essential for viral maturation, but also antagonizes interferon stimulation of the host via its deubiquitination activity. Here, we report the discovery that two SARS-CoV PL(pro) inhibitors, 6-mercaptopurine (6MP) and 6-thioguanine (6TG), as well as the immunosuppressive drug mycophenolic acid, are able to inhibit MERS-CoV PL(pro). Their inhibition mechanisms and mutually binding synergistic effect were also investigated. Our results identify for the first time three inhibitors targeting MERS-CoV PL(pro) and these can now be used as lead compounds for further antiviral drug development.

    Search related documents:
    Co phrase search for related documents
    • accession number and active site: 1
    • accession number and acute respiratory syndrome: 1, 2, 3
    • accession number and lung cancer: 1, 2
    • action pharmacological mechanism and acute respiratory syndrome: 1, 2, 3
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and low binding energy: 1, 2, 3, 4, 5, 6
    • active site and lung cancer: 1
    • active site cys and acute respiratory syndrome: 1, 2, 3, 4
    • activity spectrum and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity spectrum and lung cancer: 1
    • acute respiratory syndrome and additional effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and low binding energy: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lysis buffer: 1, 2, 3
    • additional effect and lung cancer: 1
    • low binding energy and lung cancer: 1, 2
    • lung cancer and lupus erythematosus: 1, 2, 3, 4, 5
    • lung cancer and lysis buffer: 1